Category Archives: Science: Biology

Cutting edge research is happening on a daily basis in our modern world, Keep up to date with our Press Release services.

COVID-19 Crisis Focuses Attention on Oft-Overlooked Vaccine Industry


Kalorama Information logo

As the COVID-19 outbreak advances worldwide, companies are scrambling to provide a potential vaccine. Companies from all over the world have stepped up to the challenge. There are 78 confirmed COVID-19 vaccine candidates, 5 of which have already entered clinical trials. This is documented in Kalorama Information’s recent report: Vaccine Development and Production Trends – COVID-19 and Other Vaccines Pipeline. The report presents a list of companies that have stepped up to develop a vaccine for COVID-19. The list is certain to multiply in the coming weeks as efforts are stepped up to combat COVID-19.

The report notes that although COVID is getting most of the attention, there are vaccine efforts underway for a host of diseases – including HIV, breast cancer therapeutic vaccines, malaria and Zika. Kalorama documents vaccine candidates with significant progress and those on the World Health Organization tracker.

Vaccines are often not paid much attention to compared to their pharmaceutical therapeutic brethren certainly. A few companies make them, with the help of large volume production suppliers — including egg farms and cell media vendors. Vaccines are probably the most disparate of all biologicals, and are large-volume products. Vaccine types range from relatively simple peptides to entire cells, and a limited number of manufacturing methods are available for each vaccine. Vaccines are administered in fewer and smaller doses to a much larger patient population than other biologicals. Per dosage prices are a miniscule fraction of non-vaccine biologicals and there is little manufacturer financial incentive to modify production technologies.

Prior to regulatory approval, a vaccine candidate usually undergoes three phases of development in humans, which, for the most part, progress sequentially: Phase I, Phase II, and Phase III. After successful completion of Phase III trials and following licensure of the product, Phase IV studies, doses are received by healthy individuals, thus the safety margin should be very high.

All this being said, there is remarkable progress with COVID-19 vaccines. Four companies already have vaccines in Phase 1 development, which is a remarkable accomplishment given the complexity and time needed to develop a vaccine:


  • CanSino Biologics is developing a vaccine for the prevention of COVID-19, Ad5-nCoV, a recombinant vaccine incorporating the adenovirus type 5 vector. On March 8, 2020, CanSino received approval from the Chinese authorities to being human trials. This is the first coronavirus vaccine to advance to Phase 2 trials.
  • Moderna offers its MRNA-1273, a novel lipid nanoparticle-encapsulated mRNA vaccine encoding for a perfusion stabilized form of the Spike (S) protein. On March 16, 2020, the company began its Phase 1 open-label, dose-ranging trial, occurring at Kaiser Permanente Washington Health Research Institute in Seattle.
  • Inovio Pharmaceuticals announced that CEPI provided a grant to develop a vaccine against COVID-19 called INO-4800. The company is collaborating with Beijing Advacine Biotechnology to advance the product. Preclinical testing has begun with human clinical trials to commence in April 2020 in US, China and South Korea. It is anticipated that with positive results that 1 million doses of INO-4800 DNA vaccine can be produced by the end of 2020. On April 6, 2020, the company received approval to begin Phase 1 trials. The Bill and Melinda Gates Foundation, along with other nonprofits, are putting money into Inovio’s COVID-19 vaccine project.
  • Shenzhen Geno-Immune Medical Institute offers LV-SMENP-DC vaccine. The LV-SMENP-DC vaccine is made by modifying DC with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs will be activated by LV-DC presenting Covid-19 specific antigens. The project is in Phase 1.
  • The company has a second product, Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification including immune modulatory genes and the viral minigenes, to the artificial antigen presenting cells (aAPCs). It is also in Phase 1.

Kalorama’s report details all of these projects. It can be found at: https://kaloramainformation.com/product/vaccine-development-and-production-trends-covid-19-and-other-vaccines-pipeline/

About Kalorama Information

For more than 30 years, Kalorama Information has been a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), imaging, biotechnology, healthcare, medical devices, and pharmaceuticals.

Share article on social media or email:

Microbial Discovery Group (MDG) Continues Expansion & Recruitment Plans


MDG Logo on Blue Background

Microbial Discovery Group is headquartered in Franklin, Wisconsin.

“Over the next 3-5 years, MDG expects to double its current staff of 55 employees across Wisconsin. We are actively seeking individuals who are aligned with our vision to Feed, Clean, and Save the World.”

Despite the current COVID-19 environment, MDG will continue with its expansion and recruitment plans. MDG provides critical infrastructure products for the animal feed, human consumption, wastewater, and biotech sectors, and demand for supply continues to push MDG’s previous plans for expansion. Further, as supply channels from overseas competitors have become weakened or shut down completely, new inquiries come in each day to the US-based company. Finally, certifications to produce human probiotics have been a catalyst for recent growth.

Additional centrifugation equipment arrived the second week in April, and MDG continues to build a third freeze dryer for the Franklin, WI facility. Meanwhile, MDG is finalizing plans to build a spray dryer at the Oak Creek, WI facility, having just received conditional approvals from the city. This growth is requiring MDG to recruit not only additional staff but also complete plans to expand from the current 40,000 sq. ft facility to ultimately double production, blending packaging, and warehousing space. Much of the fermentation culture drying capacity is required to maintain pace with the recent addition of two fermentors, which increased fermentation capacity 5-fold. Once the dryers are in place, this opens the door to adding a 4th fermentor in the Franklin facility. To make space for the new fermentor, MDG will tear down one laboratory and build additional laboratories at the Oak Creek location.

Expanding and recruiting during this coronavirus environment isn’t without challenges. Keeping MDG’s team members safe is the highest priority. Fortunately, the arrival of equipment and the need for on-site contractors will not happen until late summer. And while everyone at MDG hopes the safety concerns are lessened by then, there will be contingency plans in place if installations are delayed.

“At this time, we will need to hire at least ten more positions, which include fermentation, production, engineering, and maintenance roles. This production growth will cascade into requiring more business development, research, and administrative staff, triggered by revenue milestones,” stated Michael King, CEO of MDG. “Over the next 3-5 years, MDG expects to double its current staff of 55 employees across Wisconsin. For this reason, MDG continues to seek people who are aligned with our vision, which is to Feed, Clean, and Save the World.”

About Microbial Discovery Group

Microbial Discovery Group (MDG) is an R&D driven product development and Bacillus fermentation company. MDG has the capabilities to ensure success. When partnering with MDG, you can expect high quality, consistent Bacillus strain manufacturing delivered with efficiency and integrity. MDG is passionate about applying scientific principles to create indispensable solutions for our partners while working to Feed, Clean, and Save the World. For more information on Microbial Discovery Group, visit http://www.mdgbio.com/.

Share article on social media or email:

Dr. Gerald Pollack, Ph.D. Teaches Water Education For Immunity On Sharon Kleyne Hour VoiceAmerica


Sharon Kleyne, Founder of Bio Logic Aqua® Research

Sharon Kleyne, Founder of Bio Logic Aqua® Research

Air Date: 20 April 2020

Guest: Dr. Gerald Pollack, University of Washington Professor of Bioengineering, Founder & Editor of scientific journal WATER, author of The Fourth Phase of Water:Beyond Solid, Liquid & Vapor (https://www.amazon.com/Fourth-Phase-Water-Beyond-Liquid-ebook/dp/B00N2ASKF2)

https://www.voiceamerica.com/episode/123059/the-fourth-phase-of-water

*

During the virus pandemic, Bio Logic Aqua® Research Water Life Science® will be providing regular updates at http://www.sharonkleynehour.com/Coronavirus.php

*

Dr. Gerald Pollack, Ph.D. and Bio Logic Aqua® Research Water Life Science® founder and director of research Sharon Kleyne agree that common sense and a new behavior for healthy immunity are necessary as we move through this challenging time of Coronavirus and beyond it.

“I like common sense,” says Klyene. “That’s what we need to learn. Together, we need to learn about immunity protection from bacteria and viruses. With COVID-19, we learning that we need to help others learn better health habits. Take personal responsibility,” adds Kleyne, for saving other peoples’ lives and your own.”

Dr. Pollack teaches that his “general passion is uncovering scientific truth—how the world works. During his first two decades, Pollack studied muscle contraction. As a result, he learned that “there was more to water than what most people thought.” Pollack, who praises the wisdom of the ancients and time-honored practices such as Ayurveda and Traditional Chinese Medicine, says that we are mostly believers. “We try to fit information into a pre-existing model rather than observing and figuring out what is happening,” Pollack cautions.

Global Health Olympics™ lifestyle founder Kleyne agrees. “Discovery is like a hike,” says Kleyne. “You keep exploring and you keep learning.” Kleyne observes a behavioral change coming, a change in which researchers and others in medicine become more focused on finding cures rather than treating symptoms.

Building on the work of the late Gilbert Ling and others, Pollack and his colleagues discovered an Exclusion Zone in cells, an EZ where water free of particles carries a negative charge (most water carries a neutral charge). Just outside the EZ is water carrying a positive charge. “Our bodies are like a battery,” says Pollack, who reveals that this heavier, structured water in our cells is actually the water that runs our bodies.

As the late, Nobel Laureate who first isolated Vitamin C, Albert Szent-Gyorgi, once said, “Like is water dancing to the tune of solids”.

Kleyne reports, “Water is the foundation for a healthy immune system and we need to drink at least eight-to-ten glasses of clean water every day to flush toxins from the body and maintain healthy immunity.”

While we do that, Kleyne also reminds us to be grateful for first responders, clerks, farmers, truckers, medical personnel, sanitation engineers, scientists, researchers, planners and others who are helping so many people during this worldwide health and immunity crisis.

“And always remember,” says Kleyne, “to hold a child’s heart in your hands.”

*

You can listen to Sharon Kleyne’s internationally syndicated The Power of Water® & Your Health sponsored by Nature’s Tears® EyeMist® on VoiceAmerica with Program Director Rose Hong of Global Dragon TV featuring Dr. Gerald Pollack, Ph.D., discoverer of the fourth phase of water and Global Health Olympics™ Water Life Science® founder and evaporative dry eye researcher Sharon Kleyne as they discuss nutrition, water, pandemics, viruses, infectious disease, proactive care, education and evaporation, follow this link:

https://www.voiceamerica.com/episode/123059/the-fourth-phase-of-water

*

You can also tune in to recent talk radio shows with Kleyne featuring Pam Bonney (https://www.voiceamerica.com/episode/122945/how-to-protect-our-frontline-healthcare-professionals), Kevin Kearns (https://www.voiceamerica.com/episode/122821/how-to-keep-kids-strong-and-healthy-to-fight-coronavirus) and Rodrigo L. Romulo, M.D. (https://www.voiceamerica.com/episode/122421/encore-infectious-disease-101-the-fundamentals-of-controlling-and-fighting-infectious-disease).

*

If you would like to watch a brief, entertaining educational film that demonstrates the application of the new Dry Eye Solution® technology Nature’s Tears® EyeMist®, sponsor of Sharon Kleyne’s talk radio program, go here: https://www.youtube.com/watch?v=l0gOr8TB45U

Share article on social media or email:

SIUE Honors Zhi-Qing Lin with Distinguished Research Professor Rank


Zhi-Qing (Z.Q.) Lin, PhD, distinguished research professor in SIUE’s Departments of Biological Sciences and Environmental Sciences.

Dr. Lin’s research on how species of plants and mushrooms can be used as a means of cleaning contaminated soil has an immensely significant worldwide impact.

Southern Illinois University Edwardsville’s Zhi-Qing (Z.Q.) Lin, PhD, professor in the College of Arts and Sciences’ (CAS) Departments of Biological Sciences and Environmental Sciences, has achieved the University’s highest academic rank of Distinguished Research Professor.

Lin is an environmental ecologist with special research interest in phytoremediation, a biotechnical process that utilizes plants for the cleanup of trace element contamination. His research lab at SIUE conducts original research in environmental biogeochemistry of selenium, with focus on biotransformation and volatilization of selenium in the environment.

“I am honored to have received this award,” said Lin. “Selenium is an essential nutrient element for humans and animals, but in excess, it can become an environmental toxicant. It is best known as an anti-oxidant and shows anti-carcinogenic properties. Selenium intake deficiency might have affected up to one billion people worldwide. My research lab at SIUE has made efforts to explore selenium biological transformation processes in the environment, and has integrated selenium phytoremediation with the development of selenium-enriched food products for people in selenium-deficient areas.”

Since joining the SIUE faculty in 2002, Lin has received a total of $293,912 in external research grant funding for work as a principal investigator (PI), and a total of $682,284 for projects on which he has served as a co-PI or participant. His research activities at the University have been supported by major federal funding agencies including the National Science Foundation, National Institutes of Health, Department of Energy and the Environmental Protection Agency.

“Dr. Lin’s research on how species of plants and mushrooms can be used as a means of cleaning contaminated soil has an immensely significant worldwide impact,” said Jerry Weinberg, PhD, associate provost for research and dean of the SIUE Graduate School. “Natural approaches like this will save billions of dollars in pollution clean-up, and importantly, give countries that do not have the funds for pollution clean-up a practical means for making their environments safe to live in. Dr. Lin is certainly a deserving SIUE Distinguished Research Professor.”

Since his arrival at SIUE, Lin has co-edited seven books, published 30 peer-reviewed book chapters and contributed to 44 research articles in peer-reviewed scientific journals, 30 of which were co-authored by his students. Additionally, he recently co-edited “Development and Uses of Biofortified Agricultural Products,” the first book published on the subject of biofortification in the world.

“In addition to benefitting SIUE and its students, Dr. Lin’s work offers broad societal benefits,” said Elizabeth Pilon-Smits, PhD, professor of plant physiology at Colorado State University, in her recommendation letter. “Elucidating the mechanisms by which plants or fungi metabolize and accumulate or volatilize selenium and other trace elements, along with the development and optimization of remediation and biofortification technologies, is of great importance for the health of humans, livestock, wildlife and the overall environment.”

In addition to his research achievements, Lin has held numerous leadership roles at SIUE, including acting as his department’s program director and chair. He has also held several elected positions in international societies, including serving as the vice president of the International Society of Environmental Indicators and the secretary of the International Society for Selenium Research.

“Dr. Lin is one of this institution’s most prolific scholars,” agreed Vance McCraken, PhD, chair of the Department of Biological Sciences, and Nicholas Guehlstorf, PhD, chair of the Department of Environmental Sciences, in a joint letter of support. “He has developed an exceptional international reputation and has connected his work at SIUE with collaborators around the world. Since his promotion to professor, Dr. Lin has maintained the almost aggressive pace of research that he brought to SIUE as an assistant and associate professor, while also succeeding in his roles of teacher, mentor, colleague and administrator.”

Lin earned a bachelor’s in environmental biology at Liaoning University in China and a master’s in ecology at the Chinese Academy of Sciences. He went on to earn his doctorate at McGill University in Canada in 1996, and later was a postdoctoral research fellow at the University of California at Berkeley.

By preparing the next generation of leaders in a knowledge-based economy, SIUE’s Graduate School fulfills the region’s demand for highly trained professionals. Graduate school offerings include arts and sciences, business, education, engineering, nursing and interdisciplinary opportunities. SIUE professors provide students with a unique integration of theoretical education and hands-on research experiences. Students can obtain graduate certificates or pursue master’s degrees, and be part of a supportive learning and rich intellectual environment that is tailored to the needs of adult learners. The Graduate School raises the visibility of research at SIUE, which ranks highest among its Illinois Board of Higher Education peers in total research and development expenditures according to the National Science Foundation. Doctoral programs are available in the Schools of Education (EdD) and Nursing (DNP). The School of Engineering and the Department of Historical Studies feature cooperative doctoral programs (PhD), and the College of Arts and Sciences features an Environmental Resources and Policy cooperative PhD.

Share article on social media or email:

Spartan Bioscience and SUEZ partner for delivery of the world’s first on-site Legionella molecular (DNA) test


“We understand how important it is for our customers to minimize the risk of Legionella in their facilities. That’s why we’ve decided to bring Spartan’s on-site, rapid Legionella test to our customers,” said Dr. Andrew Leach.

Spartan Bioscience, a world leader in DNA diagnostics, and SUEZ’s Water Technologies and Solutions (“SUEZ”), the company’s global business unit with expertise and global capabilities to help solve the world’s toughest water, wastewater and process challenges, have partnered to bring to market the world’s first on-site molecular (qPCR) Legionella test to their customers. Spartan’s test quickly determines the amount of Legionella bacteria in a water source.

Legionella is a common bacterium that can infect the water systems of large buildings. When infected water systems release aerosolized water droplets contaminated with Legionella, building occupants can breathe in the contaminated air and contract Legionnaires’ disease, a pneumonia that is fatal in 1 in 10 people.

The recent partnership between Spartan and SUEZ brings together SUEZ’s leading water treatment service programs, and cutting-edge investments in innovation and R&D for water and process treatment, with the rapid, molecular diagnostic expertise of Spartan, to bring to market the latest innovative Legionella detection techniques.

“We understand how important it is for our customers to minimize the risk of Legionella in their facilities. That’s why we’ve decided to bring Spartan’s on-site, rapid Legionella test to our customers,” said Dr. Andrew Leach, global product manager for Monitoring Solutions at SUEZ’s Water Technologies & Solutions. “We believe this test will help our customers manage their water systems and ultimately help them mitigate Legionella contamination.”

“We are excited to partner with a world leader in water management like SUEZ. Together, we can bring the latest in on-site molecular Legionella detection to a range of customers, allowing them to react quickly and take the action needed to reduce the likelihood of a Legionella outbreak,” said Dr. Paul Lem, Chief Executive Officer and Founder at Spartan Bioscience.

Spartan developed the world’s smallest DNA analyzer with 14 years of validation behind it. Spartan’s technology has regulatory approvals worldwide such as FDA 510(k), Europe CE IVD Mark, and Health Canada; and has been used in third-party peer-reviewed publications including the New England Journal of Medicine, Lancet, and more. It is also in use by the Centers for Disease Control and Prevention (CDC) and various State Departments of Health. Spartan’s diagnostic device has been deployed in precision medicine/pharmacogenetics and environmental testing, with tests currently in development for infectious disease, veterinary diagnostics, and many more.

Spartan has received Health Canada approval for a rapid COVID-19 test that is being deployed across Canada. Rapid, in-field COVID testing has been identified as a critical component to controlling the COVID-19 pandemic.

About Spartan Bioscience

Spartan Bioscience is the leader in on-demand DNA testing. The Spartan Cube, the world’s smallest DNA analyzer, enables unprecedented portability and convenience in applications such as infectious disease, pharmacogenetics, and food and water safety testing. Spartan created the first on-site Legionella DNA test to reduce the risk of Legionnaires’ disease outbreaks in buildings. It consists of a coffee-cup-sized, portable DNA analyzer called the Spartan Cube® and single-use disposable test cartridges.

About SUEZ Water Technologies & Solutions

SUEZ offers the most comprehensive set of chemical and equipment solutions and services available, helping our customers manage and optimize their water resources and process challenges across industries and municipalities. It is their goal to enable their customers to meet increasing water demands and population needs, overcome scarcity challenges, enhance environmental stewardship and comply with regulatory requirements. SUEZ provides the advanced technologies that enable customers to leverage big data across the industrial internet to drive efficiency and promote collaboration. We partner with our customers to help them reduce costs and prepare for the evolving demands of their industry.

Share article on social media or email:

RCH Solutions Increases Support in the Greater Boston Area with the Hiring of Michael Wlodarczyk


“Adding more resources to our Boston team positions RCH to better support those we already serve as well as those who would benefit from the unmatched specialization of our model.”

RCH Solutions (RCH), a global provider of Bio-IT computing expertise for Life Sciences and Healthcare firms of all sizes, announces the hiring of Michael Wlodarczyk as Director of Sales and Business Development. Based out of RCH’s location in Boston, Mass., Wlodarczyk has been tasked to support and grow the company’s already strong presence across the Northeast.

“We continue to see increased demand for specialized scientific computing expertise in the greater Boston area,” says Michel Riener, President of RCH Solutions. “Both biotech start-ups and large pharmas alike are racing toward discovery and seeking ways to scale their R&D IT service model. Adding more resources to our Boston team positions RCH to better support those we already serve as well as those who would benefit from the unmatched specialization of our model.”

Serving Life Sciences and Healthcare companies exclusively for more than 28 years, RCH Solutions delivers focused technical computing expertise that combines scientific rigor with cross-functional IT experience. This niche service is particularly critical to biotech, pharmaceutical, and healthcare companies connecting the increasingly complex worlds of research development and technology to accelerate the advancement of scientific discovery.

Wlodarczyk joins RCH from Randstad Technologies, where he served as Recruiting Director and was responsible for leading IT staffing solutions for organizations around the globe. Growing up in Medford, New Jersey, he attended Boston College, where he played baseball until being drafted by Tampa Bay in the seventh round of the 2005 MLB draft. Wlodarczyk spent the next six years playing professional baseball, reaching AAA Durham Bulls in 2009, before finishing his career with Boston’s Brockton Rox in 2010. He started with Randstad Technologies, then Sapphire Technologies, in December of that same year.

In his new role at RCH, Wlodarczyk will use his unique understanding for the often complex and nuanced scientific-IT support needs of Life Sciences companies to serve and expand the firm’s relationships throughout the Northeast, with a concentration in the Boston area.

“This Life Sciences space is extremely competitive. To succeed—particularly in the world of R&D—teams have to be fast, agile, and, most importantly, hungry for their next breakthrough,” Riener continues. “Not only does Mike bring a depth of knowledge in areas critical to delivering the right technical computing services to our clients and prospects, his experience in professional athletics gives him a competitive edge that can’t be taught. He’s a natural fit for our team and customers in Boston.”

“Though I was immediately drawn to the opportunity to support RCH’s mission and ultimately help drive innovation in the Life Sciences, the current state of the world has only magnified the importance of those scientific initiatives,” Wlodarczyk says. “As teams navigate these uncharted waters, it’s never been more important for organizations to make sure the resources are in place to continue work at the pace necessary. I’m excited to bring my experience to this side of the business and do what I can to support the needs of the IT and scientific communities in Boston.”

About RCH Solutions

RCH Solutions (RCH) is a global provider of Bio-IT expertise, helping Life Sciences and Healthcare companies of all sizes clear the path to discovery. For more than 28 years, RCH has provided focused experience and unmatched specialization designing and deploying cross-functional IT strategies, supporting R&D infrastructure, and offering workflow best practices that solve enterprise and scientific computing challenges. Learn more at http://www.rchsolutions.com

Share article on social media or email:

Company to present update on support of its COVID-19 project using its viral vector platforms


News Image

SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene and cell therapy, today announced it will present a company update on its work expediting gene therapy research and advancing drug development during the April 2020 Virtual Investor Summit taking place on April 22 and 23. Dieter Lingelbach, the Company’s Chief Operating Officer, will also provide an update on SIRION’s new initiative to support COVID-19 research. The presentation will take place on Thursday, April 23 at 10:30 a.m. EDT followed by a live Q&A session with registered investors and other conference attendees.

A live webcast of the presentation will be available here. Following the conference, an archived version of the webcast will be available on the company’s website.

Presentation Details

Date: Thursday, April 23, 2020

Time: 10:30 a.m. EDT

Webcast link: https://bit.ly/34GtQjT

About the Virtual Investor Summit

The April 2020 Virtual Investor Summit will take place on April 22nd and 23rd from 10:00am – 3:00pm EDT. The event will feature presentations from public and private companies in multiple industries including life sciences/biotech, infrastructure and transportation. Management teams will present a live audio webcast accompanied by a slide presentation and be available to participate in virtual Q&A sessions immediately following their presentation. Investors, media and interested parties can access the event schedule and individual company webcast details at the event website, virtualinvestorsummit.com.

About SIRION Biotech GmbH

SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST™ has been used in several clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector.

Corporate Contact

Dieter Lingelbach, COO

SIRION Biotech

+49 89-700-96199-14

lingelbach@sirion-biotech.com

Media and Investor Contact USA

Lisa DeScenza

Vice President, Integrated Communications

LaVoieHealthScience

(978) 395-5970

ldescenza@lavoiehealthscience.com

Share article on social media or email:

Eighteenth Annual AutismOne Virtual Conference/Summit is FREE


AutismOneVirtualSummit.org - Register Free

AutismOne Virtual Summit – FREE – May 20 to 24

“At this critical juncture, we need to educate parents, professionals, and the public about the latest research and treatments for children with autism. A number of treatments are showing great promise and we need to continue to educate people around the world.”

Parents, professionals, and members of the public looking for the latest information on cutting-edge therapies and treatments to help children and adults with autism are invited to register for the online AutismOne Virtual Summit for FREE, scheduled for May 20 – May 24, 2020.

Children with autism get better and many recover given the proper treatments and therapies. When the underlying comorbidities of autism are properly addressed, the individual’s body can begin healing, paving the way for improved learning, function, skills, and behavior.

With over 100 expert speakers participating, the AutismOne Virtual Summit will cover key issues such as ADHD, biomedical research and treatments, and much more.

The AutismOne Conference has been the largest and most comprehensive annual autism conference internationally, since 2003, covering all domains of concern to the widest range of the autism community.

Experience the virtual person-to-person networking and learning with professionals and parents at the AutismOne Virtual Summit, where science, hope, and recovery meet. LIVE video sessions include real-time question-and-answer portions, small-group networking among attendees, and the most personal virtual experience available, utilizing the latest technologies. Parents, therapists, professionals, and students will have the opportunity to engage in conversations that cultivate meaningful relationships and obtain the skills, knowledge, and certainty to transform the lives of kids and families.

In addition, the Virtual Exhibit Hall will showcase specialty products and services from vendors specializing in addressing the needs of individuals with autism.

Past attendees say that AutismOne continues to offer the most progressive information on the bigger picture affecting families with autism.

When asked about the reasons behind creating this event, the event’ host, Ed Arranga, AutismOne’s president and co-founder said, “At this critical juncture, we need to educate parents, professionals, and the public about the latest research and treatments for children with autism. A number of treatments are showing great promise and we need to continue to educate people around the world about past successes and future directions. There are no travel costs or hotel costs, and all of the sessions are 100% free for anyone to attend the live sessions and learn from over 100 experts in the field of autism.”

The AutismOne Virtual Summit website has full details about the sessions at this year’s event. Interested parties can visit the website at https://AutismOneVirtualSummit.org

Share article on social media or email:

Young Women In Bio (YWIB) Announces Launch of YWIB Online and Availability of YWIB COVID-19 Online Resources


News Image

“The launch of YWIB Online comes at a time when there is a real need to provide young girls who cannot otherwise attend our events and programs with access to online programming in STEM…”

Young Women In Bio (YWIB) is pleased to announce the launch of its new YWIB Online platform, which includes a dedicated YouTube channel and associated Facebook page. Together, these online resources provide access to young girls across the United States and in Canada to our educational and leadership programs and other opportunities in science, technology, engineering, and math (STEM) free of charge. YWIB is launching this new initiative for young girls who are curious about STEM and want to learn more but may not live near one of our 13 chapter cities across the United States and in Montreal.

“The launch of YWIB Online comes at a time when there is a real need to provide young girls who cannot otherwise attend our events and programs with access to online programming in STEM. This will help our goal to ignite curiosity and to inspire young girls to see a future for themselves in STEM,” said Lily Wound, National Chair of YWIB. “We believe that by making these online resources available to a broader audience of girls, we can encourage more girls to find a lifelong passion and career in STEM.”

As part of our launch of YWIB Online, YWIB is excited to announce the availability of COVID-19 online resources for all students. These resources are intended to provide an opportunity to discuss the current pandemic and help students understand the biology, epidemiology, and global health risk of COVID-19. A series of informative modules outlining the science and statistics behind COVID-19, and the science behind and reason for the shelter-in-place and personal hygiene recommendations from public health officials will be included in this online area.

“With how quickly things are developing and changing, we believe that these resources on the COVID-19 pandemic will be of great help to students across the country and in Canada,” said Sarah Odeh, co-chair of the YWIB-San Francisco Bay Area chapter. “The COVID-19 modules and associated resources will hopefully answer some of the questions young people have about this pandemic and why it is so important to help flatten-the-curve.”

Along with the launch of our YWIB COVID-19 online resources area, YWIB invites student participation by offering contests and additional activities. Students, parents, and teachers can visit here for updates on the offerings on our YWIB Online platform, including to our COVID-19 online resources.

ABOUT YOUNG WOMEN IN BIO (YWIB)

Young Women In Bio (YWIB) gives girls today the inspiration and support they need to become

tomorrow’s leaders in science, technology, engineering, and math (STEM). We strive to provide

education and hands-on experience in STEM, as well as share our passion for all scientific fields. Through 13 chapters across the United States and Canada, YWIB partners with leading companies, universities, hospitals, and other organizations to host highly engaging, educational, and motivational programs for young girls interested in STEM. To learn more, visit: http://www.womeninbio.org/ywib.

ABOUT WOMEN IN BIO (WIB)

Founded in 2002 to support women employed in the field of life sciences from the classroom to the boardroom, Women In Bio (WIB) is a multifaceted organization with 13 chapters across North America and Montreal. It offers an array of professional educational programs, peer to peer learning, mentoring and networking opportunities, and is the only organization for women that integrates all career levels and life sciences fields. WIB is funded by sponsors and partners dedicated to supporting women of all ages in their lifelong journey in the life sciences and beyond. Please visit http://www.womeninbio.org.

Contact: Marsha Morgenstern

Women In Bio (WIB) Communication and Marketing Administrator

mmorgenstern@womeninbio.org

412-223-7855

http://www.womeninbio.org

Share article on social media or email:

National Business Research Institute Recognizes Bioventus for their Commitment to Employee Engagement


Bioventus

Bioventus

Employee Engagement drives Financial Performance. This award is a result of Bioventus’ dedication to measuring and improving their Employee Engagement.

The National Business Research Institute (NBRI) is pleased to welcome Bioventus to the NBRI Circle of Excellence. The NBRI Circle of Excellence Award recognizes organizations that place a high value on Employee and Customer engagement. These organizations demonstrate their dedication by conducting best in class survey research with NBRI and taking action based upon the results. NBRI commends the leadership of these organizations for their commitment to the Continuous Improvement Process and recognizes their achievements with the Circle of Excellence Award.

To qualify for this honor, the organization must score within Stretch Performance at the 75th benchmarking percentile when measured against their industry, or the organization must improve 5 or more benchmarking percentiles in total company score over the previous research study, a statistically significant amount. It is no small feat to move an entire company’s score of customer loyalty or employee engagement 5 or more percentiles, or to reach Stretch or Best in Class Performance levels.

“Employee Engagement drives Financial Performance,” said Dr. Jan G. West, Ph.D., CEO & Organizational Psychologist at NBRI. “This award is a result of Bioventus’ dedication to measuring and improving their Employee Engagement.”

“Bioventus is pleased to record a score within the NBRI’s Stretch Performance benchmark and we are determined to improve on engagement with our people worldwide,” said Leigh Ann Stradford, Senior Vice President and Chief Human Resources Officer, Bioventus. “We believe a strong employee value proposition and alignment to our culture principles are the foundation for engagement as well as recruitment and retention of our employees.”

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit https://www.BioventusGlobal.com.

About NBRI

NBRI conducts Employee, Customer, and Market Research for businesses, and uses this data to help organizations leverage these human factors to make improvements to operations and strategy. With its extensive experience across all industries, NBRI’s research teams bring their clients a combination of deep industry knowledge and expert advice. NBRI’s mission is to help their Clients set new standards of excellence in their industries. NBRI product offerings, such as the Root Cause Analysis, ensures their clients will focus on the most impactful issues.

National Business Research Institute, Inc.

2701 Dallas Parkway; Suite 650

Plano, TX 75093

972-612-5070

800-756-6168

https://www.nbrii.com/

Bioventus

Thomas Hill

919-474-6715

thomas.hill@bioventusglobal.com

Share article on social media or email: